Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 18.94 EUR 0.37% Market Closed
Market Cap: 18.6B EUR
Have any thoughts about
Bayer AG?
Write Note

Bayer AG
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bayer AG
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Bayer AG
XETRA:BAYN
Total Current Assets
€33.1B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
3%
ATAI Life Sciences NV
NASDAQ:ATAI
Total Current Assets
$185.6m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck KGaA
XETRA:MRK
Total Current Assets
€13.9B
CAGR 3-Years
11%
CAGR 5-Years
1%
CAGR 10-Years
7%
MPH Health Care AG
XETRA:93M1
Total Current Assets
€7.1m
CAGR 3-Years
18%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Dermapharm Holding SE
XETRA:DMP
Total Current Assets
€623.1m
CAGR 3-Years
10%
CAGR 5-Years
15%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Total Current Assets
€62.8m
CAGR 3-Years
41%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Bayer AG
Glance View

Market Cap
18.6B EUR
Industry
Pharmaceuticals

Bayer AG, a German multinational behemoth, traces its roots back to 1863 in Barmen, when Friedrich Bayer and Johann Friedrich Weskott began their enterprise as a dye-making factory. Fast forward to the present day, and Bayer has evolved into a global powerhouse, seamlessly weaving through pharmaceuticals, consumer health, and agricultural science. At its core, Bayer’s business operations spin around its three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division is the jewel in Bayer’s crown, focusing on prescription medicines across various therapeutic areas such as oncology, cardiology, and gynecology, allowing Bayer to cater to the world's increasing demand for healthcare solutions, which not only drive patient outcomes but also account for a significant chunk of revenue. Not to be overshadowed, Bayer’s Crop Science division plays a pivotal role, emphasizing its strong commitment to sustainable agriculture. Here, the company develops seeds, traits, and crop protection products that appeal to farmers seeking to enhance yield and manage crop threats. Meanwhile, the Consumer Health division targets over-the-counter products, covering a range of everyday health issues, resonating with consumers seeking self-care solutions. Bayer’s ability to seamlessly integrate its scientific prowess into real-world applications enables the company to extract value across these sectors, creating an intricate mosaic of interdependent streams of revenue and continually reinforcing its stature as a leader in life sciences.

BAYN Intrinsic Value
110.32 EUR
Undervaluation 83%
Intrinsic Value
Price

See Also

What is Bayer AG's Total Current Assets?
Total Current Assets
33.1B EUR

Based on the financial report for Sep 30, 2024, Bayer AG's Total Current Assets amounts to 33.1B EUR.

What is Bayer AG's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
3%

Over the last year, the Total Current Assets growth was -12%. The average annual Total Current Assets growth rates for Bayer AG have been 1% over the past three years , and 3% over the past ten years .

Back to Top